tirzepatide peter attia on semaglutide Insights I'm a Doctor. Why I – Peter Attia on X: "This

1,7,8 A clinical trial specifically examining GLP-1 agonists in MS patients is currently underway, and results from randomised trials will help establish whether these medications have genuine disease-modifying effects

By stimulating these receptors, tirzepatide enhances insulin secretion when blood sugar levels rise, helping to lower glucose levels after meals

Quick Summary GLP-1 agonists are effective for diabetes and obesity but may not be ideal for healthy non-diabetics

The extended half-life justifies once-weekly subcutaneous administration and produces sustained GLP-1 receptor occupancy throughout the dosing interval